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ABSTRACT 
Our study aimed to assess and compare the bioavailability of Eptoin 100 mg and Epileptin 100mg tablets in Nepalese healthy volunteers. A 
randomized, two-treatment cross-over study with two weeks’ wash-out period was conducted in 12 healthy non-smoker and non-alcoholic 
Nepalese male volunteers over a period of 6 months in the department of Clinical Pharmacology and Therapeutic at B. P. Koirala Institute of 
Health Sciences, Dharan, Nepal after approval from the Institutional Review Committee. The participants were randomized using sealed 
envelope system and received a single 100 mg oral tablet of either of the formulations with a two week washout period. Blood samples were 
collected predose and at regular intervals postdose upto 72 hours. Plasma phenytoin levels were estimated by reverse phase high performance 
liquid chromatography. The analytical method was validated prior to the start of study. Cmax (Peak Plasma Concentration), Tmax (Time to achieve 
maximum Plasma Concentration), AUC0-72 (Area under plasma concentration time curve 0 to 72 hours), AUC0-∞ (Area under plasma 
concentration time curve 0 to ∞) and T½ (Elimination half-life) and Kel (Elimination rate constant) were calculated and 80-120% margin (90% 
confidence interval) was used to assess bioequivalence. ANOVA test was used to analyze the data at P-value of 0.05. All volunteers completed the 
study. The log-transformed values of Cmax, Tmax, AUC0-t, and AUC0-∞ of the both formulations were within the specified limits and were 
bioequivalent according to the regulatory definition of bioequivalence based on the rate and extent of absorption. Both products can be 
considered equally effective in medical practice. 
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INTRODUCTION 
Phenytoin is one of the most widely used drug in partial and 
tonic-clonic seizure. Its pharmacokinetic is changed from 
first-order to zero-order at high dose. Its rate of absorption 
also differs markedly with different brand formulation and 
hence its plasma concentration may vary and ultimately 
affect seizure control.1,2 As various national and 
international brands of phenytoin are available in Nepal, 
their substitution may affect its bioavailability and affect the 
clinical response and cause intolerable adverse effects.3,4 
Some patient may switch to cheaper brand of phenytoin 
which may not be bioequivalent to the parent drug and it 
ultimately affect seizure control. The generic phenytoin was 
associated with an increase in serum concentration as 
compared to its branded formulation in a study conducted in 
the USA.5 Changing from brand formulation of phenytoin to a 
generic has resulted in new seizure attacks. Physicians, 
pharmacists, patients and policy makers should be aware 
that for some patients there may be risks associated with 
switching from brand to generic formulation of phenytoin.6  
It is the priority of the health care professionals and the 
policy makers to make the country self-reliant in essential 
drugs production and to ensure the availability of safe, 
effective, standard, and quality drugs at affordable price in 
quantities sufficient to cover the health needs of general 
population. To achieve the same objective, domestic 
pharmaceuticals should be promoted. In spite of the large 
number of phenytoin brands available in Nepal, none has 
compared the bioavailability of commonly prescribed 
formulations. The United States Food and Drug 
Administration (USFDA) considers two products to be 
therapeutic equivalents if they are bioequivalent.7 
Bioequivalent study is considered as the gold-standard 
method for comparing two brand formulation of same drug.8 
Single-dose bioequivalent studies are generally more 
sensitive than multiple dose studies.9 Therefore this study 
was aimed to assess and compare the bioavailability of 
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Eptoin 100 mg (Acme formulation Pvt. Ltd., India) and 
Epileptin 100mg (Asian pharmaceuticals Pvt. Ltd., Nepal) in 
Nepalese healthy volunteers. 
MATERIALS AND METHODS 
Type of study and its Setting: A randomized, two-
treatment cross-over study with two weeks’ wash-out period 
was conducted in the department of Clinical Pharmacology 
and Therapeutic at B. P. Koirala Institute of Health Sciences 
(BPKIHS), Dharan, Nepal over a period of 6 months.  
Selection of participants: This study was conducted in 12 
healthy non-smoker and non-alcoholic Nepalese male 
volunteers (aged 17-45years and within 20% of their ideal 
body-weight). According to international guidelines 
bioequivalence study should be performed on a minimum of 
12 subjects to ensure a power of at least 80%.10 Exclusion 
criteria were history of hypersensitivity to phenytoin, 
history or presence of gastrointestinal, liver or kidney 
disease, or any other conditions known to interfere with the 
absorption, distribution, metabolism or excretion of common 
medications; history or presence of cardiovascular or 
hematological disease, any clinically significant illness during 
the 4 weeks prior to day 1 of this study, maintenance therapy 
with any drug or history of drug dependence, alcohol abuse, 
or serious neurological or psychological disease; 
participation in a new drug study in the last 6 months; HIV 
and Australian Antigen positive subjects; clinically relevant 
abnormal physical and/or clinical findings at the screening; 
any drug intake in the last 30 days; donated blood in the 
previous month. 
Ethical approval: The ethical clearance was taken from the 
institutional ethical committee. This study was carried out in 
accordance with the clinical research guidelines established 
by the basic principles defined in the International 
Conference on Harmonization guidelines for Good Clinical 
Practice, Nepal Health Research Council guidelines for 
biomedical research on human subjects and the principles 
enunciated in the Declaration of Helsinki. 
Study procedure: The study participants were randomized 
using sealed envelope system to avoid bias of treatment 
allocation. After overnight fasting of at least 10 hours, single 
dose of Eptoin 100mg tablet (reference drug) was given to 6 
participants and Epileptin 100mg tablets (test drug) was 
given to the other 6 participants with 240ml water. A total of 
10 blood samples were collected from anti-cubital vein at 0 
hours (just before drug administration), 1.0, 2.0, 3.0, 4.0, 6.0, 
8.0, 24.0, 48.0 and 72.0 hours in centrifuge tubes containing 
ethylene diamine tetraacetic acid. The blood samples were 
centrifuged immediately at 5000 r.p.m. for 10 minutes, the 
plasma was separated into duplicate polypropylene tubes 
and stored frozen at -20ᵒC. Before assaying the plasma was 
allowed to reach room temperature, vortexed, centrifuged 
and the residual clot was removed.  
Analysis by HPLC: The concentration of the drugs in the 
blood samples were analyzed by reverse phase high 
performance liquid chromatography (HPLC) method 
(Knauer HPLC, Germany). The analytical method was 
validated prior to beginning of the study. The column 
consisted of Knauer C18, 250 X 4.6mm, 5μ particle size with 
C18 guard column, stainless steel. The mobile phase used 
was acetonitrile. The flow rate used was 1 ml/minute. The 
samples were analyzed at detection wavelength of 215 nm. 
Fixed loop Rheodyne injector system fitted with a 20μl 
Rheodyne Loop was used. Integrating software was Clarity 
Chrome. Photodiode array detector (Smart line 2800) from 
Knauer, Germany was used. Calibration samples were 
prepared by spiking 480 μL of control human plasma with 20 
μL of working stock solution of analyte. The plasma 
concentration-time profile of phenytoin was determined 
using the zero moment non-compartmental 
pharmacokinetics method. The plasma drug level profile was 
presented in graphical forms. The following pharmacokinetic 
parameters of test drug (Epileptin) and reference drug 
(Eptoin) were calculated for each subject: Cmax (Peak Plasma 
Concentration), Tmax (Time to achieve maximum Plasma 
Concentration), AUC0-72 (Area under plasma concentration 
time curve 0 to 72 hours), AUC0-∞ (Area under plasma 
concentration time curve 0 to ∞), T½ (Elimination half-life) 
and Kel (Elimination rate constant). 
Statistical analysis: Descriptive parameters mean and 
standard deviation (SD) were calculated using SPSS version 
11.5. ANOVA test was applied on untransformed (Cmax, AUC0-
72, AUC0-∞) and log-transformed pharmacokinetic data (Cmax, 
AUC0-72, AUC0-∞). P value of 0.05 or less was considered 
statistically significant. The products of phenytoin were 
considered to be bioequivalent if the 90% confidence 
interval of difference in the average values of logarithmic 
AUC and Cmax between test and reference drugs was within 
the acceptable range of Log (0.8) to Log (1.25).8,11,12 
RESULTS 
The mean age, weight, height, and body mass index (BMI) of 
the participants were 33.67 ± 9.75 years, 62.58 ± 12.92 kg, 
161.29 ± 4.20 cm and 24.09 ± 5.03 kg/m2 respectively. There 
was no incidence of any adverse event during the study 
period. All the volunteers completed the study in good 
health. Pharmacokinetic parameters of Eptoin and Epileptin 
are given in Table 1. 
 
 
Table 1: Pharmacokinetic parameters (mean) of Eptoin and Epileptin (n=12) 
Pharmacokinetic 
parameters (mean±SD) 
Brand formulation of Phenytoin  
P-value Eptoin Epileptin 
Cmax (µg/ml) 1.882±0.725 1.920±0.696 0.235* 
tmax (h) 6.750±5.723 5.917±1.832 0.126* 
AUC0-72  (µg h/ml) 64.949±38.309 65.486±36.674 0.324* 
AUC0-∞ (µg h/ml) 91.343±85.302 93.369±89.818 0.152* 
Kel (h-1) 0.032±0.014 0.034±0.016 0.241* 
t1/2 (h) 28.139±17.935 28.496±23.968 0.148* 
*Statistically not significant at P-value of 0.05 
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Time-concentration curve of Eptoin (test drug) and Epileptin (reference drug) is shown in figure 1.  
 
Figure 1: Mean time-concentration graph of twelve volunteers for test and reference preparation (n=12) 
 
It was found that there was no statistically significant 
difference between test and reference drugs of in terms of 
Cmax, lnCmax, Tmax, lnTmax, AUC0-t, lnAUC0-t, AUC0-t, ln AUC0-∞. 
Both drugs were found to be bioequivalent as 90% 
confidence interval for Cmax and lnCmax (index of rate of 
absorption), AUC0-t, lnAUC0-t, AUC0-∞ and lnAUC0-∞ (index of 
extent of absorption) values of Epileptin (test drug) were 
within the accepted limit (80% to 125%) of that of the 
Eptoin (reference drug) as shown in Table 2. 
 
Table 2: 90% Confidence Intervals of the ratios (Eptoin/Epileptin) of pharmacokinetic parameters (n=12) 
Pharmacokinetic 
parameters 
90% Confidence interval 
Untransformed Data Ln transformed Data  
Cmax (µg/ml) 0.93-1.11 0.88-1.23 
AUC0-t (µg h/ml) 0.96-1.06 0.99-1.02 
AUC0-∞ (µg h/ml) 0.86-1.18 0.98-1.04 
 
DISCUSSION 
The US FDA has approved generic versions of phenytoin 
based on single-dose bioequivalence studies that required 
the 90% confidence intervals to fall within 80% to 125% of 
the originator product. The most important objective of 
bioequivalence study is to guarantee patients that generic 
products are safe and clinically effective within certain 
boundaries.13-15 This study was conducted to compare the 
bioavailability of two tablet formulations of phenytoin 
sodium in twelve Nepalese healthy volunteers at a tertiary 
center in Eastern Nepal.  It was a small scale randomized, 
two-way complete cross-over bioequivalence study with a 
two weeks wash-out period. After decoding the treatment 
allocation, twelve were in period I and twelve were in period 
II. All twelve subjects completed the study and received both 
the reference and the test drug alternately according to the 
randomization allocated in period I and period II. There was 
no dropout. 
The maximum plasma concentration (Cmax) of Eptoin 100mg 
tablet was 1.882±0.725 μg/ml at the time 6.750±5.723 hr 
(Tmax) whereas the maximum plasma concentration of 
Epileptn 100mg tablet was 1.920±0.696 μg/ml (Cmax) at the 
time 5.917±1.832 hr (Tmax). The rate of absorption for the 
Eptoin (reference drug) and Epileptin (test drug) were 
similar as evidenced by their Cmax and Tmax values. The extent 
of absorption of the test and reference preparation were also 
similar as the plasma concentration time curve up to infinity 
(AUC0-∞) of reference drug was 91.343±85.302 μghr/ml, 
whereas that of the test drug was 93.369±89.818 μghr/ml. 
Analysis of variance for log transformed pharmacokinetic 
parameters revealed that there was no significant effect of 
variation due to period and formulation for all the 
pharmacokinetic parameters. The study showed that both 
test and reference drug demonstrated comparable rate and 
extent of absorption. Overall, the test drug analyzed in the 
study satisfied the criteria for bioequivalence versus 
reference drug since the 90% CI interval of Cmax and AUC0-t 
and AUC0-∞ were within the specified limit of 80 to 120% for 
untransformed data and 80-125% for log-transformed data. 
Thus it can be claimed that test drug is bioequivalent to 
reference drug as per USFDA guidelines. The two 
formulations under the investigation demonstrated 
comparable rate and extent of absorption in healthy human 
volunteers under fasting conditions. Statistical analysis 
demonstrated that sequence and period effects did not occur. 
This finding partially supports another relevant issue on 
generic drug prescription as patients requiring long term 
drug treatment are likely to receive over time generic copies 
of the same active ingredient manufactured by different 
companies. With particular regard to drugs with narrow 
therapeutic index like phenytoin the results of the present 
study has to be cautiously interpreted in clinical setting with 
proper therapeutic drug monitoring as patients might be 
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subjected to variations of the steady-state pharmacokinetic 
parameters after multiple dosing. 
Bioequivalence study of phenytoin has been done previously 
in different parts of the world by different researchers and 
institutions; however there were contradictory results on 
bioequivalence study. Gibberd et al studied the comparative 
bioavailability of two brands of phenytoin and found no 
significant difference between phenytoin levels for either 
preparation.16  Similarly in another study, Meyer et al had 
determined inter-lot and intra-subject variability and effect 
of gender and menstrual cycle in the bioavailability of the 
100mg extended phenytoin sodium capsules and found that 
there was very little difference in the bioavailability of the 
three lots of phenytoin.17 In a study conducted in India, 
Gogtay et al had compared the bioavailability of a single oral 
200mg dose of four brands (Dilantin, Epsolin, M-toin and 
Eptoin) of phenytoin and found that M-toin and Eptoin are 
bioequivalent but other brands were not.18 These variations 
may be due to several factors including use of excipients in 
the different formulations. So, for inter-changeability of 
phenytoin only those preparations that are shown to be 
bioequivalent should be prescribed with therapeutic 
monitoring of the individual patients. Our study did not 
provide independent estimates of intra-subject variabilities 
since each subject received the same treatment only once. 
Female participants were not included as we did not get the 
written consent from them. As the data were obtained from 
healthy subjects who were administered a single dose, the 
pharmacokinetics parameters of phenytoin might differ in 
target populations. Effect on food on absorption was also not 
assessed. 
CONCLUSIONS 
Our study found that Epileptin 100mg was bioequivalent to 
Eptoin 100mg according to the regulatory definition of 
bioequivalence based on the rate and extent of absorption. 
Both products can be considered equally effective in medical 
practice and were well tolerated. Further studies are needed 
to compare these drug formulations in Nepalese patients. 
Therapeutic drug monitoring should be done during 
switching of brand formulation of phenytoin in epilepsy. 
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